121 related articles for article (PubMed ID: 11603217)
1. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
Halperin R; Zehavi S; Hadas E; Habler L; Bukovsky I; Schneider D
Int J Gynecol Pathol; 2001 Oct; 20(4):341-5. PubMed ID: 11603217
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.
Halperin R; Zehavi S; Dar P; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(4):292-6. PubMed ID: 11695812
[TBL] [Abstract][Full Text] [Related]
3. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses.
Zhang C; Li XP; Cui H; Shen DH; Wei LH
J Zhejiang Univ Sci B; 2008 Jun; 9(6):435-40. PubMed ID: 18543395
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
5. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Int J Gynecol Cancer; 2001; 11(5):403-8. PubMed ID: 11737473
[TBL] [Abstract][Full Text] [Related]
6. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
7. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
[TBL] [Abstract][Full Text] [Related]
9. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
10. Primary peritoneal serous papillary carcinoma: a clinical and pathological study.
Liu Q; Lin JX; Shi QL; Wu B; Ma HH; Sun GQ
Pathol Oncol Res; 2011 Sep; 17(3):713-9. PubMed ID: 21647781
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis.
Nafisi H; Ghorab Z; Ismill N; Dubé V; Plotkin A; Han G; Cesari M; Lu FI; Saad R; Khalifa M; Nofech-Mozes S
Int J Gynecol Pathol; 2015 Sep; 34(5):424-36. PubMed ID: 26107560
[TBL] [Abstract][Full Text] [Related]
12. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
13. Uterine papillary serous carcinoma evolves via a p53-driven pathway.
Moll UM; Chalas E; Auguste M; Meaney D; Chumas J
Hum Pathol; 1996 Dec; 27(12):1295-300. PubMed ID: 8958301
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
16. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
Ben-Baruch G; Sivan E; Moran O; Rizel S; Menczer J; Seidman DS
Gynecol Oncol; 1996 Mar; 60(3):393-6. PubMed ID: 8774644
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
[TBL] [Abstract][Full Text] [Related]
18. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
19. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
20. Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study.
Suo Z; Karbovo E; Trope CG; Metodiev K; Nesland JM
Ultrastruct Pathol; 2004; 28(3):141-7. PubMed ID: 15471427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
